GSK plc
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $103.3B
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $103.3B
- Dividend yield
- 3.64%
- Shares outstanding
- 2.0B
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 18, 1976
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 17% below its 52-week high.
- Pays a dividend yielding about 3.64% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review GSK plc.
Write a review
News about GSK plc
News & sentiment via Polygon.io
